Literature DB >> 24910766

Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.

Gautam Patel1, Norma E Roncal2, Patricia J Lee2, Susan E Leed2, Jessey Erath3, Ana Rodriguez4, Richard J Sciotti2, Michael P Pollastri1.   

Abstract

Hesperadin, an established human Aurora B inhibitor, was tested against cultures of Trypanosoma brucei, Leishmania major, and Plasmodium falciparum, and was identified to be a potent proliferation inhibitor. A series of analogs was designed and tested to establish the initial structure-activity relationships for each parasite. In this study, we identified multiple non-toxic compounds with high potency against T. brucei and P. falciparum with good selectivity. These compounds may represent an opportunity for continued optimization.

Entities:  

Year:  2014        PMID: 24910766      PMCID: PMC4045489          DOI: 10.1039/C4MD00045E

Source DB:  PubMed          Journal:  Medchemcomm        ISSN: 2040-2503            Impact factor:   3.597


  14 in total

1.  Pharmacological validation of Trypanosoma brucei phosphodiesterases B1 and B2 as druggable targets for African sleeping sickness.

Authors:  Nicholas D Bland; Cuihua Wang; Craig Tallman; Alden E Gustafson; Zhouxi Wang; Trent D Ashton; Stefan O Ochiana; Gregory McAllister; Kristina Cotter; Anna P Fang; Lara Gechijian; Norman Garceau; Rajiv Gangurde; Ron Ortenberg; Mary Jo Ondrechen; Robert K Campbell; Michael P Pollastri
Journal:  J Med Chem       Date:  2011-11-08       Impact factor: 7.446

2.  Target repurposing for neglected diseases.

Authors:  Michael P Pollastri; Robert K Campbell
Journal:  Future Med Chem       Date:  2011-08       Impact factor: 3.808

3.  The human Aurora kinase inhibitor danusertib is a lead compound for anti-trypanosomal drug discovery via target repurposing.

Authors:  Stefan O Ochiana; Vidya Pandarinath; Zhouxi Wang; Rishika Kapoor; Mary Jo Ondrechen; Larry Ruben; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2012-07-31       Impact factor: 6.514

4.  Kinase scaffold repurposing for neglected disease drug discovery: discovery of an efficacious, lapatinib-derived lead compound for trypanosomiasis.

Authors:  Gautam Patel; Caitlin E Karver; Ranjan Behera; Paul J Guyett; Catherine Sullenberger; Peter Edwards; Norma E Roncal; Kojo Mensa-Wilmot; Michael P Pollastri
Journal:  J Med Chem       Date:  2013-05-03       Impact factor: 7.446

5.  The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms.

Authors:  Neal Jetton; Karen G Rothberg; James G Hubbard; John Wise; Yan Li; Haydn L Ball; Larry Ruben
Journal:  Mol Microbiol       Date:  2009-03-06       Impact factor: 3.501

6.  Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy.

Authors:  Kayode K Ojo; J Robert Gillespie; Aaron J Riechers; Alberto J Napuli; Christophe L M J Verlinde; Frederick S Buckner; Michael H Gelb; Mathias M Domostoj; Susan J Wells; Alexander Scheer; Timothy N C Wells; Wesley C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

7.  Inhibitors of human histone deacetylase with potent activity against the African trypanosome Trypanosoma brucei.

Authors:  John M Kelly; Martin C Taylor; David Horn; Einars Loza; Ivars Kalvinsh; Fredrik Björkling
Journal:  Bioorg Med Chem Lett       Date:  2012-01-28       Impact factor: 2.823

8.  An essential Aurora-related kinase transiently associates with spindle pole bodies during Plasmodium falciparum erythrocytic schizogony.

Authors:  Luc Reininger; Jonathan M Wilkes; Hélène Bourgade; Diego Miranda-Saavedra; Christian Doerig
Journal:  Mol Microbiol       Date:  2010-11-10       Impact factor: 3.501

9.  The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing.

Authors:  Rosario Diaz-Gonzalez; F Matthew Kuhlmann; Cristina Galan-Rodriguez; Luciana Madeira da Silva; Manuel Saldivia; Caitlin E Karver; Ana Rodriguez; Stephen M Beverley; Miguel Navarro; Michael P Pollastri
Journal:  PLoS Negl Trop Dis       Date:  2011-08-23

10.  From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules.

Authors:  Andrew Woodland; Raffaella Grimaldi; Torsten Luksch; Laura A T Cleghorn; Kayode K Ojo; Wesley C Van Voorhis; Ruth Brenk; Julie A Frearson; Ian H Gilbert; Paul G Wyatt
Journal:  ChemMedChem       Date:  2013-06-14       Impact factor: 3.466

View more
  23 in total

1.  EVALUATION OF AROMATIC 6-SUBSTITUTED THIENOPYRIMIDINES AS SCAFFOLDS AGAINST PARASITES THAT CAUSE TRYPANOSOMIASIS, LEISHMANIASIS, AND MALARIA.

Authors:  Jennifer L Woodring; Gautam Patel; Jessey Erath; Ranjan Behera; Patricia J Lee; Susan E Leed; Ana Rodriguez; Richard J Sciotti; Kojo Mensa-Wilmot; Michael P Pollastri
Journal:  Medchemcomm       Date:  2015-02       Impact factor: 3.597

2.  Optimization of physicochemical properties for 4-anilinoquinazoline inhibitors of trypanosome proliferation.

Authors:  Jennifer L Woodring; Kelly A Bachovchin; Kimberly G Brady; Mitchell F Gallerstein; Jessey Erath; Scott Tanghe; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Michael P Pollastri
Journal:  Eur J Med Chem       Date:  2017-10-06       Impact factor: 6.514

3.  Series of Alkynyl-Substituted Thienopyrimidines as Inhibitors of Protozoan Parasite Proliferation.

Authors:  Jennifer L Woodring; Ranjan Behera; Amrita Sharma; Justin Wiedeman; Gautam Patel; Baljinder Singh; Paul Guyett; Emanuele Amata; Jessey Erath; Norma Roncal; Erica Penn; Susan E Leed; Ana Rodriguez; Richard J Sciotti; Kojo Mensa-Wilmot; Michael P Pollastri
Journal:  ACS Med Chem Lett       Date:  2018-09-04       Impact factor: 4.345

4.  Design, Synthesis, and Characterization of Novel Small Molecules as Broad Range Antischistosomal Agents.

Authors:  Anastasia Rugel; Reid S Tarpley; Ambrosio Lopez; Travis Menard; Meghan A Guzman; Alexander B Taylor; Xiaohang Cao; Dmytro Kovalskyy; Frédéric D Chevalier; Timothy J C Anderson; P John Hart; Philip T LoVerde; Stanton F McHardy
Journal:  ACS Med Chem Lett       Date:  2018-09-14       Impact factor: 4.345

5.  Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery.

Authors:  William Devine; Jennifer L Woodring; Uma Swaminathan; Emanuele Amata; Gautam Patel; Jessey Erath; Norma E Roncal; Patricia J Lee; Susan E Leed; Ana Rodriguez; Kojo Mensa-Wilmot; Richard J Sciotti; Michael P Pollastri
Journal:  J Med Chem       Date:  2015-07-08       Impact factor: 7.446

6.  New compound sets identified from high throughput phenotypic screening against three kinetoplastid parasites: an open resource.

Authors:  Imanol Peña; M Pilar Manzano; Juan Cantizani; Albane Kessler; Julio Alonso-Padilla; Ana I Bardera; Emilio Alvarez; Gonzalo Colmenarejo; Ignacio Cotillo; Irene Roquero; Francisco de Dios-Anton; Vanessa Barroso; Ana Rodriguez; David W Gray; Miguel Navarro; Vinod Kumar; Alexander Sherstnev; David H Drewry; James R Brown; Jose M Fiandor; J Julio Martin
Journal:  Sci Rep       Date:  2015-03-05       Impact factor: 4.379

7.  Structure-Bioactivity Relationship for Benzimidazole Thiophene Inhibitors of Polo-Like Kinase 1 (PLK1), a Potential Drug Target in Schistosoma mansoni.

Authors:  Thavy Long; R Jeffrey Neitz; Rachel Beasley; Chakrapani Kalyanaraman; Brian M Suzuki; Matthew P Jacobson; Colette Dissous; James H McKerrow; David H Drewry; William J Zuercher; Rahul Singh; Conor R Caffrey
Journal:  PLoS Negl Trop Dis       Date:  2016-01-11

8.  Structural optimization and evaluation of novel 2-pyrrolidone-fused (2-oxoindolin-3-ylidene)methylpyrrole derivatives as potential VEGFR-2/PDGFRβ inhibitors.

Authors:  Ting-Hsuan Yang; Chun-I Lee; Wen-Hsin Huang; An-Rong Lee
Journal:  Chem Cent J       Date:  2017-08-01       Impact factor: 4.215

Review 9.  Kinases as druggable targets in trypanosomatid protozoan parasites.

Authors:  Christopher Merritt; Lisseth E Silva; Angela L Tanner; Kenneth Stuart; Michael P Pollastri
Journal:  Chem Rev       Date:  2014-10-07       Impact factor: 60.622

10.  Identification of "Preferred" Human Kinase Inhibitors for Sleeping Sickness Lead Discovery. Are Some Kinases Better than Others for Inhibitor Repurposing?

Authors:  Emanuele Amata; Hualin Xi; Gonzalo Colmenarejo; Rosario Gonzalez-Diaz; Carlos Cordon-Obras; Manuela Berlanga; Pilar Manzano; Jessey Erath; Norma E Roncal; Patricia J Lee; Susan E Leed; Ana Rodriguez; Richard J Sciotti; Miguel Navarro; Michael P Pollastri
Journal:  ACS Infect Dis       Date:  2016-01-17       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.